Narlı Özdemir Zehra, Kılıçaslan Necati Alp, Yılmaz Musa, Eşkazan Ahmet Emre
Department of Hematology, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Int J Hematol. 2023 Jan;117(1):3-15. doi: 10.1007/s12185-022-03446-1. Epub 2022 Sep 5.
Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a life expectancy comparable to that of the general population thanks to the use of tyrosine kinase inhibitor (TKI) therapies. Although most patients with CML require lifelong TKI therapy, it is possible for some patients to achieve treatment-free remission. These spectacular results have been made possible by the development of superior treatment modalities as well as clinicians' efforts in strictly adhering to clinical guidelines such as the National Comprehensive Cancer Network (NCCN) and European Leukemia Network (ELN). CML treatment recommendations reported in these guidelines are the result of years of selecting and incorporating the most reliable evidence. In this review, we provide a synopsis of the differences and similarities that exist between the NCCN and ELN guidelines.
由于使用了酪氨酸激酶抑制剂（TKI）疗法，目前处于慢性期的慢性髓性白血病（CML）患者的预期寿命可与普通人群相当。虽然大多数CML患者需要终身接受TKI治疗，但部分患者有可能实现无治疗缓解。卓越治疗方式的发展以及临床医生严格遵循诸如美国国立综合癌症网络（NCCN）和欧洲白血病网络（ELN）等临床指南的努力，使得这些显著成果成为可能。这些指南中报道的CML治疗建议是多年来筛选并纳入最可靠证据的结果。在本综述中，我们概述了NCCN和ELN指南之间存在的异同。
